210 related articles for article (PubMed ID: 31774020)
1. Pneumococcal conjugate vaccines decrease community-acquired alveolar pneumonia with and without pleural effusion in children <60 months in Southern Israel, 2002-2016.
Triadou D; Givon-Lavi N; Greenberg D; Ben-Shimol S
Infect Dis (Lond); 2020 Mar; 52(3):186-195. PubMed ID: 31774020
[No Abstract] [Full Text] [Related]
2. Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.
Greenberg D; Givon-Lavi N; Ben-Shimol S; Ziv JB; Dagan R
Vaccine; 2015 Aug; 33(36):4623-9. PubMed ID: 26116251
[TBL] [Abstract][Full Text] [Related]
3. Use of Chest Radiography Examination as a Probe for Pneumococcal Conjugate Vaccine Impact on Lower Respiratory Tract Infections in Young Children.
Ben-Shimol S; Dagan R; Givon-Lavi N; Avital D; Bar-Ziv J; Greenberg D
Clin Infect Dis; 2020 Jun; 71(1):177-187. PubMed ID: 31414125
[TBL] [Abstract][Full Text] [Related]
4. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children.
Angoulvant F; Levy C; Grimprel E; Varon E; Lorrot M; Biscardi S; Minodier P; Dommergues MA; Hees L; Gillet Y; Craiu I; Zenkhri F; Dubos F; Guen CG; Launay E; Martinot A; Cohen R
Clin Infect Dis; 2014 Apr; 58(7):918-24. PubMed ID: 24532543
[TBL] [Abstract][Full Text] [Related]
5. Comparative incidence dynamics and serotypes of meningitis, bacteremic pneumonia and other-IPD in young children in the PCV era: Insights from Israeli surveillance studies.
Ben-Shimol S; Givon-Lavi N; Grisaru-Soen G; Megged O; Greenberg D; Dagan R;
Vaccine; 2018 Aug; 36(36):5477-5484. PubMed ID: 28579230
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of Severe and Non-severe Invasive Pneumococcal Disease in Young Children in Israel Following PCV7/PCV13 Introduction.
Glikman D; Dagan R; Barkai G; Averbuch D; Guri A; Givon-Lavi N; Ben-Shimol S;
Pediatr Infect Dis J; 2018 Oct; 37(10):1048-1053. PubMed ID: 29750768
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal nasopharyngeal carriage in children <5 years of age visiting the pediatric emergency room in relation to PCV7 and PCV13 introduction in southern Israel.
Ben-Shimol S; Givon-Lavi N; Greenberg D; Dagan R
Hum Vaccin Immunother; 2016; 12(2):268-76. PubMed ID: 26430921
[TBL] [Abstract][Full Text] [Related]
8. A Prospective, Population-based Study to Determine the Incidence and Bacteriology of Bacterial Conjunctivitis in Children <2 Years of Age Following 7-Valent and 13-Valent Pneumococcal Conjugate Vaccine Sequential Implementation.
Dagan R; Ben-Shimol S; Greenberg D; Givon-Lavi N
Clin Infect Dis; 2021 Apr; 72(7):1200-1207. PubMed ID: 32140705
[TBL] [Abstract][Full Text] [Related]
9. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance.
Ben-Shimol S; Regev-Yochay G; Givon-Lavi N; van der Beek BA; Brosh-Nissimov T; Peretz A; Megged O; Dagan R; ;
Clin Infect Dis; 2022 May; 74(9):1639-1649. PubMed ID: 34293091
[TBL] [Abstract][Full Text] [Related]
10. Long-term Association of 13-Valent Pneumococcal Conjugate Vaccine Implementation With Rates of Community-Acquired Pneumonia in Children.
Ouldali N; Levy C; Minodier P; Morin L; Biscardi S; Aurel M; Dubos F; Dommergues MA; Mezgueldi E; Levieux K; Madhi F; Hees L; Craiu I; Gras Le Guen C; Launay E; Zenkhri F; Lorrot M; Gillet Y; Béchet S; Hau I; Martinot A; Varon E; Angoulvant F; Cohen R
JAMA Pediatr; 2019 Apr; 173(4):362-370. PubMed ID: 30715140
[TBL] [Abstract][Full Text] [Related]
11. Near-elimination of otitis media caused by 13-valent pneumococcal conjugate vaccine (PCV) serotypes in southern Israel shortly after sequential introduction of 7-valent/13-valent PCV.
Ben-Shimol S; Givon-Lavi N; Leibovitz E; Raiz S; Greenberg D; Dagan R
Clin Infect Dis; 2014 Dec; 59(12):1724-32. PubMed ID: 25159581
[TBL] [Abstract][Full Text] [Related]
12. PCV13-vaccinated children still carrying PCV13 additional serotypes show similar carriage density to a control group of PCV7-vaccinated children.
Dagan R; Juergens C; Trammel J; Patterson S; Greenberg D; Givon-Lavi N; Porat N; Gruber WC; Scott DA
Vaccine; 2017 Feb; 35(6):945-950. PubMed ID: 28087146
[TBL] [Abstract][Full Text] [Related]
13. Impact of infant 13-valent pneumococcal conjugate vaccine on serotypes in adult pneumonia.
Rodrigo C; Bewick T; Sheppard C; Greenwood S; Mckeever TM; Trotter CL; Slack M; George R; Lim WS
Eur Respir J; 2015 Jun; 45(6):1632-41. PubMed ID: 25792633
[TBL] [Abstract][Full Text] [Related]
14. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Somekh E; Aviner S; Miron D; Dagan R
Vaccine; 2014 Jun; 32(27):3452-9. PubMed ID: 24690148
[TBL] [Abstract][Full Text] [Related]
15. The impact of heptavalent pneumococcal conjugate vaccine on the incidence of childhood community-acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Japan.
Naito S; Tanaka J; Nagashima K; Chang B; Hishiki H; Takahashi Y; Oikawa J; Nagasawa K; Shimojo N; Ishiwada N
Epidemiol Infect; 2016 Feb; 144(3):494-506. PubMed ID: 26122538
[TBL] [Abstract][Full Text] [Related]
16. Impact of the 13-valent pneumococcal conjugate vaccine on the incidences of community-acquired pneumonia and pneumonia-related hospitalizations in children ≤5 years after its implementation into the national immunization program of Turkey.
Gönüllü E; Soysal A; Yıldız I; Aydemir G; Tunç T; Karaböcüoğlu M
Hum Vaccin Immunother; 2020 Oct; 16(10):2504-2508. PubMed ID: 32119602
[TBL] [Abstract][Full Text] [Related]
17. Complicated community acquired pneumonia in children prior to the introduction of the pneumococcal conjugated vaccine.
Goldbart AD; Leibovitz E; Porat N; Givon-Lavi N; Drukmann I; Tal A; Greenberg D
Scand J Infect Dis; 2009; 41(3):182-7. PubMed ID: 19117244
[TBL] [Abstract][Full Text] [Related]
18. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
[TBL] [Abstract][Full Text] [Related]
19. Impact of PCV7/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD.
Ben-Shimol S; Greenberg D; Givon-Lavi N; Schlesinger Y; Miron D; Aviner S; Dagan R;
Vaccine; 2016 Aug; 34(38):4543-4550. PubMed ID: 27475471
[TBL] [Abstract][Full Text] [Related]
20. The herd effects of infant PCV7/PCV13 sequential implementation on adult invasive pneumococcal disease, six years post implementation; a nationwide study in Israel.
Regev-Yochay G; Katzir M; Strahilevitz J; Rahav G; Finn T; Miron D; Maor Y; Chazan B; Schindler Y; Dagan R;
Vaccine; 2017 Apr; 35(18):2449-2456. PubMed ID: 28342668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
